Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immuneactivation
Autore:
Jaffee, EM; Hruban, RH; Biedrzycki, B; Laheru, D; Schepers, K; Sauter, PR; Goemann, M; Coleman, J; Grochow, L; Donehower, RC; Lillemoe, KD; OReilly, S; Abrams, RA; Pardoll, DM; Cameron, JL; Yeo, CJ;
Indirizzi:
Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA Johns Hopkins Med Inst Baltimore MD USA 21205 ol, Baltimore, MD 21205 USA Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA Johns Hopkins Med Inst Baltimore MD USA 21205 rg, Baltimore, MD 21205 USA Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA Johns HopkinsMed Inst Baltimore MD USA 21205 ol, Baltimore, MD 21205 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 1, volume: 19, anno: 2001,
pagine: 145 - 156
SICI:
0732-183X(20010101)19:1<145:NAGCF>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
AUTOLOGOUS MELANOMA-CELLS; MHC CLASS-I; ANTITUMOR IMMUNITY; METASTATIC MELANOMA; GROVERS-DISEASE; CLINICAL-TRIAL; GENE-TRANSFER; DRUG-THERAPY; ANTIGENS; ADENOCARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Jaffee, EM Johns Hopkins Univ, Bunting Blaustein Canc Res Bldg,Room 4M07,1650 Or, Baltimore, MD 21231 USA Johns Hopkins Univ Bunting Blaustein Canc Res Bldg,Room 4M07,1650 Or Baltimore MD USA 21231
Citazione:
E.M. Jaffee et al., "Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immuneactivation", J CL ONCOL, 19(1), 2001, pp. 145-156

Abstract

Purpose: Allogeneic granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines can cure established tumors in the mouse, but their efficacy against human tumors is uncertain. We have developed a novelOM-CSF-secreting pancreatic tumor vaccine. To determine its safety and ability to induce antitumor immune responses, we conducted a phase I trial in patients with surgically resected adenocarcinoma of the pancreas. Patients and Methods: Fourteen patients with stage 1, 2, or 3 pancreatic adenocarcinoma were enrolled. Eight weeks after pancreaticoduodenectomy, three patients received 1 x 10(7) vaccine cells, three patients received 5 x 10(7) vaccine cells, three patients received 10 x 10(7) vaccine cells, and five patients received 50 x 10(7) vaccine cells. Twelve of 14 patients then went on to receive a 6-month course of adjuvant radiation and chemotherapy. One month after completing adjuvant treatment, six patients still in remission received up to three additional monthly vaccinations with the same vaccine dose that they had received originally. Results: No dose-limiting toxicities were encountered. Vaccination inducedincreased delayed-type hypersensitivity (DTH) responses to autologous tumor cells in three patients who had received greater than or equal to 10 x 10(7) vaccine cells. These three patients also seemed to have had an increased disease-free survival time, remaining disease-free at least 25 months after diagnosis. Conclusion: Allogeneic GM-CSF-secreting tumor vaccines are safe in patients with pancreatic adenocarcinoma. This vaccine approach seems to induce dose-dependent systemic antitumor immunity as measured by increased postvaccination DTH responses against autologous rumors. Further clinical evaluation of this approach in patients with pancreatic cancer is warranted. J Clin Oncol 19:145-156. (C) 2001 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 22:18:11